Elettra-Sincrotrone Trieste S.C.p.A. website uses session cookies which are required for users to navigate appropriately and safely. Session cookies created by the Elettra-Sincrotrone Trieste S.C.p.A. website navigation do not affect users' privacy during their browsing experience on our website, as they do not entail processing their personal identification data. Session cookies are not permanently stored and indeed are cancelled when the connection to the Elettra-Sincrotrone Trieste S.C.p.A. website is terminated.
More info

Inhibition of PD-1/PD-L1 protein-protein interaction

Novel PD-1/PD-L1 protein-protein interaction inhibitors were designed and evaluated for activity and mechanism using XRD2 structural data.

(Ref: Basu E. et al, JMedChem, 62(15), 7520-7263 (2019))

The programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint serves to mediate peripheral immune tolerance and to protect against excessive inflammation and autoimmunity. Several tumors evoke immunosuppressive mechanisms to evade immune system attacks. Cancer immunotherapies targeting the PD1/PD-L1 immune checkpoint pathway have reversed the immunosuppression defensive approaches, resulting in remarkable clinical effects. A series of C2-symmetric inhibitors was designed and evaluated for inhibitory activity against the PD-1/PD-L1 protein-protein interaction (IC50’s in the nM range). X-ray structural studies provided structural insights into the interaction, using XRD2 data.

Retrieve Article
Design, synthesis, evaluation and structural studies of C2-symmetric small molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) protein-protein interaction,
Subhadwip Basu, Jeffrey Yang, Bin Xu, Katarzyna Magiera-Mularz, Lukasz Skalniak, Bogdan Musielak, Vladyslav Kholodovych, Tadeuz A. Holak and Longqin Hu
Journal of Medicinal Chemistry 2019 62(15), 7520-7263, doi: 10.1021/acs.jmedchem.9b00795, PDB: 6RPG
Last Updated on Sunday, 29 September 2019 13:58